| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKCI |
| Uniprot No | P41743 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-596aa |
| 氨基酸序列 | PTQRDSSTM SHTVAGGGSG DHSHQVRVKA YYRGDIMITH FEPSISFEGL CNEVRDMCSF DNEQLFTMKW IDEEGDPCTV SSQLELEEAF RLYELNKDSE LLIHVFPCVP ERPGMPCPGE DKSIYRRGAR RWRKLYCANG HTFQAKRFNR RAHCAICTDR IWGLGRQGYK CINCKLLVHK KCHKLVTIEC GRHSLPQEPV MPMDQSSMHS DHAQTVIPYN PSSHESLDQV GEEKEAMNTR ESGKASSSLG LQDFDLLRVI GRGSYAKVLL VRLKKTDRIY AMKVVKKELV NDDEDIDWVQ TEKHVFEQAS NHPFLVGLHS CFQTESRLFF VIEYVNGGDL MFHMQRQRKL PEEHARFYSA EISLALNYLH ERGIIYRDLK LDNVLLDSEG HIKLTDYGMC KEGLRPGDTT STFCGTPNYI APEILRGEDY GFSVDWWALG VLMFEMMAGR SPFDIVGSSD NPDQNTEDYL FQVILEKQIR IPRSLSVKAA SVLKSFLNKD PKERLGCHPQ TGFADIQGHP FFRNVDWDMM EQKQVVPPFK PNISGEFGLD NFDSQFTNEP VQLTPDDDDI VRKIDQSEFE GFEYINPLLM SAEECV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PRKCI(蛋白激酶C iota型)重组蛋白的相关文献概览：
1. **文献名称**：*"PKCι promotes ovarian tumor progression through deregulation of cyclin E"*
**作者**：Fields AP 等(2015)
**摘要**：研究利用重组PRKCI蛋白揭示其在卵巢癌细胞中通过磷酸化调控Cyclin E蛋白稳定性，促进细胞周期进程和肿瘤增殖的分子机制。
2. **文献名称**：*"Structural basis for the interaction of PKCι with the scaffold protein Par6"*
**作者**：Sasaki AT 等(2012)
**摘要**：通过重组PRKCI蛋白的体外结合实验及晶体结构分析，阐明了PRKCI与Par6蛋白的结合界面及其在细胞极性调控中的关键作用。
3. **文献名称**：*"Recombinant PKCι kinase activity drives lung cancer cell invasion via NF-κB signaling"*
**作者**：Justilien V 等(2017)
**摘要**：利用重组PRKCI激酶活性检测，证明其通过激活NF-κB通路促进非小细胞肺癌细胞的侵袭转移，为靶向治疗提供依据。
注：以上文献信息为基于领域研究的概括性示例，实际引用时需核对具体文献来源。
PRKCI (Protein Kinase C Iota) is a member of the atypical protein kinase C (aPKC) family, which plays critical roles in cell polarity, proliferation, survival, and cancer progression. Unlike classical PKC isoforms, PRKCI lacks calcium-dependent activation and is constitutively active in various cellular contexts. It functions as an oncogene in multiple cancers, including lung, ovarian, and glioblastoma, where its overexpression correlates with poor prognosis and therapy resistance. PRKCI operates within key signaling pathways, such as the PI3K/AKT and RAS/RAF cascades, and interacts with polarity proteins like PAR6 to regulate cell junction formation and asymmetric division. Structurally, PRKCI contains a PB1 domain for protein-protein interactions and a kinase domain responsible for phosphorylating downstream targets like MEK5 and JNK.
Recombinant PRKCI protein is engineered for research and therapeutic applications. Produced using expression systems like mammalian or insect cells, it retains post-translational modifications essential for its enzymatic activity. This recombinant tool enables in vitro studies of PRKCI's kinase activity, substrate specificity, and inhibitor screening. Researchers use it to investigate mechanisms underlying cancer metastasis, stem cell maintenance, and drug resistance. Additionally, it aids in developing targeted therapies, such as aPKC inhibitors, to disrupt oncogenic signaling. Recent studies also explore PRKCI's role in neurodegenerative diseases and immune regulation, broadening its biomedical relevance. Overall, PRKCI recombinant protein serves as a vital resource for dissecting its biological functions and translating findings into clinical interventions.
×
